ASTH
Astrana Health, Inc.
ASTH's fundamentals are strong: revenue grew 35% and earnings per share more than tripled. At 30x earnings, it's trading below its usual 34x. Analysts expect that strong growth to continue, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ASTH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Stable |
ASTH's revenue and profitability are currently healthy, and its cash flow and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ASTH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $31.77 | — |
| Cheap | 26x | $28.12 | -11% |
| Current | 30x | $31.77 | — |
| Fair | 34x | $35.99 | +13% |
| Expensive | 61x | $65.79 | +107% |
Historical ranges are pointers, not guarantees.
ASTH's PE is in its cheap range at 30x. If earnings grow as analysts expect, today's price would be 18x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ASTH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
ASTH has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ASTH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.77 | +65% |
| Q3 2026 | $1.07 | +435% |
| Q2 2026 | $0.82 | +58% |
| Q1 2026 | $0.61 | -16% |
| Q4 2025 | $0.46 | -49% |
| Q3 2025 | $0.20 | -85% |
| Q2 2025 | $0.52 | -64% |
| Q1 2025 | $0.73 | -45% |
| Q4 2024 | $0.90 | -30% |
ASTH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ASTH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +7.1% |
| Q2 2026 | $972.5M | +49% |
| Q1 2026 | $965.1M | +56% |
| Q4 2025 | $950.5M | +43% |
| Q3 2025 | $956M | +100% |
| Q2 2025 | $654.8M | +35% |
| Q1 2025 | $620.4M | +53% |
| Q4 2024 | $665.2M | +88% |
ASTH has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.9% | +1.9 points |
| Q2 2026 | 3.5% | +0.4 points |
| Q1 2026 | 3% | -0.4 points |
| Q4 2025 | 1.9% | +1.8 points |
| Q3 2025 | 2% | -3.9 points |
| Q2 2025 | 3.1% | -3.1 points |
| Q1 2025 | 3.3% | -4.1 points |
| Q4 2024 | 0.1% | +1.2 points |
ASTH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ASTH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.4M | +68% |
| Q2 2026 | $28.9M | -68% |
| Q1 2026 | $64.1M | +372% |
| Q4 2025 | -$6M | +$7.5M |
| Q3 2025 | $7.4M | -77% |
| Q2 2025 | $89.5M | +340% |
| Q1 2025 | $13.6M | +142% |
| Q4 2024 | -$13.5M | -210% |
ASTH generated $99M in free cash flow over the past year, up 2.5% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ASTH on cash flow, with more consistent year-over-year improvement.
ASTH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +138K shares |
| 1 year | +0.9% | +443K shares |
| 3 years | +6.4% | +3M shares |
| 5 years | +8.9% | +4.1M shares |
| Available history | +33% | +12.5M shares |
ASTH has 50M diluted shares, up 0.9% from a year ago, despite $19M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1M |
| Q2 2026 | — |
| Q1 2026 | $2.8M |
| Q4 2025 | $15M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $10.6M |
| Q4 2023 | $503,000 |
ASTH spent $19M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ASTH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ASTH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 4.9x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.3x | Healthy |
ASTH's net debt is about 2.9 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ASTH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.9 | Neutral |
| Stochastic | 28.8 | Neutral |
ASTH's weekly RSI is 41 (neutral) and its Stochastic is 29 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ASTH PE vs Healthcare Sector
| Metric | ASTH | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 15% above |
| PE % | 30 | 29 | 1 pt above |
ASTH is trading at 30x earnings, a 15% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ASTH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.9 | 11% below |
| 20 week MA | $38.4 | 17% below |
| 50 week MA | $32.8 | 3% below |
| 100 week MA | $31.0 | 2.6% above |
| 200 week MA | $35.1 | 9.6% below |
ASTH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ASTH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.7 | $17.5 | -6.3% |
| 2021 | $17.5 | $70.8 | +305% |
| 2022 | $70.8 | $29.9 | -58% |
| 2023 | $29.9 | $38.3 | +28% |
| 2024 | $38.3 | $32.7 | -15% |
| 2025 | $32.7 | $25.4 | -22% |
| 2026 YTD | $25.4 | $31.8 | +25% |
ASTH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.